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MaBACKGROUND Cardiovascular complications are major clinical problems in type 2 diabetes mellitus (T2DM). The au-
thors previously demonstrated a crucial role of red blood cells (RBCs) in control of cardiac function through arginase-
dependent regulation of nitric oxide export from RBCs. There is alteration of RBC function, as well as an increase in
arginase activity, in T2DM.
OBJECTIVES The authors hypothesized that RBCs from patients with T2DM induce endothelial dysfunction by up-
regulation of arginase.
METHODS RBCs were isolated from patients with T2DM and age-matched healthy subjects and were incubated with rat
aortas or human internal mammary arteries from nondiabetic patients for vascular reactivity and biochemical studies.
RESULTS Arginase activity and arginase I protein expression were elevated in RBCs from patients with T2DM (T2DM
RBCs) through an effect induced by reactive oxygen species (ROS). Co-incubation of arterial segments with T2DM RBCs,
but not RBCs from age-matched healthy subjects, signiﬁcantly impaired endothelial function but not smooth muscle cell
function in both healthy rat aortas and human internal mammary arteries. Endothelial dysfunction induced by T2DM RBCs
was prevented by inhibition of arginase and ROS both at the RBC and vascular levels. T2DM RBCs induced increased
vascular arginase I expression and activity through an ROS-dependent mechanism.
CONCLUSIONS This studydemonstrates anovelmechanismbehind endothelial dysfunction inT2DMthat is inducedbyRBC
arginase I and ROS. Targeting arginase I in RBCs may serve as a novel therapeutic tool for the treatment of endothelial
dysfunction in T2DM. (J Am Coll Cardiol 2018;72:769–80) © 2018 by the American College of Cardiology Foundation.T ype 2 diabetes mellitus (T2DM) is an impor-tant risk factor for cardiovascular diseases,including atherosclerosis and ischemic heart
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ABBR EV I A T I ON S
AND ACRONYMS
ABH = 2(S)-amino-6-
boronohexanoic acid
EC = endothelial cell
EDR = endothelium-dependent
relaxation
EIR = endothelium-
independent relaxation
eNOS = endothelial nitric oxide
synthase
GK = Goto-Kakizaki
H2O2 = hydrogen peroxide
Healthy RBC = red blood cell
from healthy subjects
KH = Krebs-Henseleit
NAC = N -acetyl-cysteine
NADPH = nicotinamide
adenine dinucleotide
phosphate
NO = nitric oxide
NOS = nitric oxide synthase
NOX = nicotinamide adenine
dinucleotide phosphate oxidase
RBC = red blood cell
ROS = reactive oxygen species
T2DM = type 2 diabetes
mellitus
T2DM RBC = red blood cell
from patients with type 2
diabetes mellitus
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Author's Personal Copyvasoconstrictors, and proinﬂammatory mol-
ecules including reactive oxygen species
(ROS) (1). The pathogenesis of endothelial
dysfunction in T2DM is complex and multi-
factorial, and this may explain why
glucose-lowering therapy has not convinc-
ingly reduced mortality among patients at
high risk for cardiovascular events (2).
Therefore, there is an unmet need to iden-
tify key disease mechanisms behind
vascular complications in T2DM to develop
novel therapies that speciﬁcally target such
complications.SEE PAGE 781Impaired NO bioavailability occurs early
and contributes to progression and prog-
nosis of cardiovascular complications in
T2DM. NO is produced from L-arginine by
endothelial NO synthase (eNOS), which
competes with arginase for their common
substrate, L-arginine (3). The expression and
activity of the 2 isoforms arginase I and II
are increased in cardiovascular diseases,
including T2DM triggered by several factors
including glucose and ROS (3). The
increased arginase activity is an important
cause of endothelial dysfunction in T2DM as
a result of the competition with eNOS for
L-arginine and excessive ROS formation
stemming from uncoupled eNOS, nicotin-
amide adenine dinucleotide phosphate(NADPH) oxidase (NOX), or mitochondrial complexes
(3). Accordingly, arginase inhibition markedly im-
proves endothelial function in patients with T2DM, a
ﬁnding suggesting that arginase may serve as a po-
tential therapeutic target for improvement of
vascular function (4,5).
Red blood cells (RBCs) may play a fundamental
role in cardiovascular homeostasis, by contributing
to vascular function and integrity independently
from their function as oxygen transporters (6).
RBCs undergo functional alterations in T2DM,
including reduced NO bioavailability (7) or
enhanced oxidative stress (8), which subsequently
may affect vascular function. We demonstrated a
crucial role of RBCs in control of cardiac function
through arginase-dependent regulation of export of
NO-like bioactivity from RBCs, thus suggesting a
direct interaction of RBCs with cardiovascular
function (9). However, key mechanisms behind the
interaction of RBCs with the vasculature and their
importance in cardiovascular diseases are unclear
and elusive. Previous studies suggested thatarginase is up-regulated in RBCs from patients with
T2DM (10,11). The functional implications of this
ﬁnding are unknown but may imply a possible
causative role of RBC arginase for endothelial
dysfunction in T2DM.
Therefore, the present study was designed to test
the hypothesis that RBCs from patients with T2DM
induce endothelial dysfunction and that this effect is
mediated by up-regulation of arginase and ROS for-
mation. We demonstrate a detrimental effect of
RBCs from patients with T2DM on endothelial func-
tion through up-regulation of arginase at both RBC
and vascular levels. In addition, we show that RBCs
increase endothelial cell (EC) arginase activity and
expression through an ROS-dependent mechanism.
These results demonstrate a novel role of RBCs in
the development of endothelial dysfunction in
T2DM.
METHODS
All experimental protocols regarding human mate-
rials were conducted according to the Declaration of
Helsinki and were approved by the regional ethical
review board in Stockholm. All subjects were
informed of the purpose and gave their oral and
written consent. All protocols regarding animal
studies were approved by the regional ethical com-
mittee and conformed to the Guide for Care and Use
of Laboratory Animals published by the U.S. National
Institutes of Health (NIH publication no. 85-23,
revised 1996). An expanded methods section is
available in the Online Appendix.
RBC-TISSUE CO-INCUBATION AND FUNCTIONAL
EXPERIMENTS. RBCs were isolated from patients and
rats with T2DM. Subsequently, RBCs were diluted
with Krebs-Henseleit (KH) or serum-free culture me-
dium to a hematocrit of 45% or 10%, and were incu-
bated with aortic rings isolated from rats or internal
mammary arteries (IMAs) from nondiabetic patients
in cell culture incubator at 37C with 5% carbon di-
oxide for 18 h or 1 h. Control arteries were incubated
with isolated RBCs from healthy controls, with KH
buffer, or with supernatant from RBCs that under-
went 18 h incubation. Following incubation, the ves-
sels were thoroughly washed and mounted in wire
myograph for determination of endothelium-
dependent relaxation (EDR) and endothelium-
independent relaxations (EIR) by cumulatively
increasing concentrations (10-9 to 10-5 M) of acetyl-
choline and sodium nitroprusside, respectively.
Additional RBCs and RBC-incubated vessels were
subjected to molecular analysis. The same protocols
were repeated in the presence of various inhibitors
TABLE 1 Basal Characteristics of Subjects
Healthy Subjects
(n ¼ 34)
Type 2 Diabetes
(n ¼ 46)
Age, yrs 61  7 60  12
Male 31 36
BMI, kg/m2 25.0  2.7 30.6  5.1*
Systolic BP, mm Hg 134  16 137  16
Diastolic BP, mm Hg 81  8 79  9
Fasting glucose, mM 5.7  0.5 11.4  3.2*
Smokers 1 7
HbA1c, mmol/mol 36  3 70  20*
Hemoglobin, g/l 144  8 139  17
Creatinine, mmol/l 83  14 88  29
Triglycerides, mmol/l 1.1  0.4 1.9  1.0*
Total cholesterol, mmol/l 5.2  0.9 4.3  1.3*
HDL, mmol/l 1.5  0.4 1.1  0.3*
LDL, mmol/l 3.2  0.8 2.2  1.0*
Vascular complications
Coronary artery disease 0 7
Retinopathy 0 6
Neuropathy 0 5
Nephropathy 0 5
Peripheral vascular disease 0 5
Medications
ACE inhibitor/ARB 0 27
Aspirin 0 18
Lipid lowering 0 37
b-blocker 0 12
Calcium-channel blocker 0 12
Insulin 0 31
Metformin 0 31
GLP-1 analogue 0 14
DPP-4i 0 9
SU 0 2
SGLT2i 0 3
Values are mean  SD or n. *p < 0.001 versus healthy subjects.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker;
BMI ¼ body mass index; BP ¼ blood pressure; DPP-4i ¼ dipeptidyl peptidase-4
inhibitor; GLP-1 ¼ glucagon like peptide-1; HbA1c ¼ glycosylated hemoglobin;
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; SGLT2i ¼ sodium-
glucose co-transporter inhibitor; SU ¼ sulfonylurea.
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Author's Personal Copyagainst arginase, NOX, ROS, and hydrogen peroxide
(H2O2).
STATISTICS. Concentration-response curves were
analyzed with 2-way analysis of variance with
repeated measurement. Differences between 2 groups
were determined with the t-test or nonparametric
equivalent, depending on distribution. Analyses of 3
or more groups were determined with 1-way analysis
of variance. Data are presented as mean  SEM unless
otherwise indicated; p <0.05 was considered statis-
tically signiﬁcant.
RESULTS
BASAL CHARACTERISTICS. Basal characteristics are
shown in Table 1. The patients with T2DM had higher
body mass index, fasting glucose, glycated hemoglo-
bin, and triglycerides, whereas they had lower total
cholesterol, high-density lipoprotein, and low-
density lipoprotein cholesterol in comparison with
the healthy subjects. Seven of the patients with T2DM
and 1 of the healthy subjects were smokers at the time
of inclusion. None of the healthy subjects took
medication.
To evaluate endothelial function in vivo in
patients with T2DM and healthy subjects, forearm
endothelium-dependent vasodilation and endothelium-
independent vasodilation were determined (4). Base-
line forearm ﬂow did not differ signiﬁcantly between
patients with T2DM (37.4  5.0 ml/min/1,000 ml)
and healthy subjects (29.1  2.6 ml/min/1,000 ml).
Endothelium-dependent vasodilation was signiﬁ-
cantly lower in patients with T2DM than in healthy
subjects (Online Figure 1A), whereas endothelium-
independent vasodilation did not differ (Online
Figure 1B).
RBCs FROM PATIENTS WITH T2DM INDUCE
ENDOTHELIAL DYSFUNCTION. EDR and EIR of rat
aortic rings were determined following 18 h co-
incubation with RBCs. EDR was signiﬁcantly
impaired following incubation with RBCs (hematocrit
w45%) from patients with T2DM (T2DM RBCs),
whereas it was unaffected by RBCs from healthy
subjects (Healthy RBCs) in comparison with incuba-
tion in KH buffer (Figure 1A). EIR was unaffected by
T2DM RBCs (Figure 1B), a ﬁnding suggesting that the
RBCs selectively impair endothelial function. Incu-
bation with T2DM RBCs at w10% hematocrit for 18 h
or at w45% hematocrit for 1 h did not induce endo-
thelial dysfunction (Online Figures 2A and 2B). Incu-
bation with the supernatant collected from isolated
RBCs diluted in buffer to hematocrit 45% stored for
18 h or from the ﬁnal washing step of RBCs did not
affect endothelial function, a ﬁnding demonstratingthat the endothelial dysfunction was mediated by the
RBCs (Online Figures 2C and 2D). T2DM RBCs also
induced endothelial dysfunction in human internal
mammary arteries (Figure 1C), whereas internal
mammary artery smooth muscle cell function was not
affected (Figure 1D). T2DM RBCs induced endothelial
dysfunction irrespective of whether the patients were
receiving statin treatment or not (Online Figure 2E).
EDR was also impaired in healthy rat aortas incubated
with RBCs from Goto-Kakizaki (GK) rats (12) to an
extent similar to that observed in GK rat aortas
incubated with KH buffer (Online Figure 2F). EIR was
not affected in aortas from nondiabetic rats incubated
with RBCs from GK rats or aortas from GK rats incu-
bated with KH buffer (Online Figure 2G). T2DM RBCs
FIGURE 1 RBCs From Patients With T2DM Impair Endothelial Function
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(A and C) Endothelium-dependent relaxation to acetylcholine (ACh) and (B and D) endothelium-independent relaxation to sodium nitro-
prusside (SNP) in isolated rat aortas (A and B, n ¼ 5 to 9) and human internal mammary arteries (IMAs) (C and D, n ¼ 3 to 5) incubated with
buffer, red blood cells from healthy subjects (Healthy RBCs), and red blood cells from patients with type 2 diabetes mellitus (T2DM RBCs) for
18 h. Values are mean  SEM. *p < 0.05, **p < 0.01 versus buffer or healthy red blood cells representing the concentration-response
relation by 2-way analysis of variance.
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Author's Personal Copyor RBCs from GK rats incubated with aortas from GK
rats did not induce additional endothelial dysfunc-
tion beyond that observed after incubation with
Healthy RBCs or buffer (Online Figures 2H and 2I).
RBC ARGINASE AND ROS ACCOUNT FOR
ENDOTHELIAL DYSFUNCTION IN T2DM. Next, we
investigated whether RBC arginase and ROS account
for the development of endothelial dysfunction.
Co-incubation with the arginase inhibitor 2(S)-amino-
6-boronohexanoic acid (ABH) for 18 h prevented the
impairment of EDR induced by T2DM RBCs in rat
aortas (Figure 2A). Moreover, ROS scavenging by
N-acetyl-cysteine (NAC) prevented endothelial
dysfunction induced by T2DM RBCs (Figure 2B). Theinvolvement of ROS is likely derived from NOX iso-
form 2 (NOX2) because the nonselective NOX inhibi-
tor apocynin (Figure 2C) and the selective NOX2
inhibitor gp91 ds-tat (Figure 2D) markedly attenuated
the impairment in EDR. By contrast, the NOX1 in-
hibitors ML171 (Figure 2E) and NoxA1ds (data not
shown) did not block the effect. The H2O2 decompo-
sition catalyst catalase prevented the development of
impaired EDR (Figure 2F). None of these inhibitors
affected EDR following incubation with Healthy RBCs
(Online Figures 3A to 3E) or KH buffer (Online
Figures 4A to 4F), with the exception that EDR was
reduced by catalase in aortas incubated with Healthy
RBCs (Online Figure 3F).
FIGURE 2 Functional Involvement of RBC Arginase and ROS in Endothelial Dysfunction in T2DM
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Endothelium-dependent relaxation to ACh in isolated rat aortas following incubation with buffer, Healthy RBCs, and T2DM RBCs for 18 h. RBCs from patients with T2DM
were co-incubated with (A) the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) (n ¼ 8), (B) the reactive oxygen species (ROS) scavenger N-acetyl-cysteine
(NAC) (n ¼ 9), (C) the reduced nicotinamide adenine dinucleotide phosphate oxidase (NOX) inhibitor apocynin (n ¼ 6), (D) the selective NOX2 inhibitor gp 91 ds-tat
(n ¼ 6), (E) the selective NOX1 inhibitor ML171 (n ¼ 6), and (F) the hydrogen peroxide decomposition catalyst catalase (n ¼ 5). Values are mean  SEM. *p <0.05,
**p <0.01 versus buffer; †p <0.05, ††p <0.01 effect of RBCs with drug versus RBCs without drug representing the concentration-response relation by 2-way analysis
of variance. Abbreviations as in Figure 1.
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Author's Personal CopyTo test whether there were carryover effects by the
pharmacological inhibitors from the co-incubation
with RBCs to the functional studies, aortic rings iso-
lated from wild-type (WT) and GK rats were pre-
incubated with KH buffer for 18 h in the absence and
presence of ABH, NAC, and catalase. The impaired
EDR in GK rat aortas was not affected by those in-
hibitors (Online Figures 5A to 5C). By contrast, EDR of
the GK rat aortas was improved when these aortas
were pre-incubated with and exposed to the inhibitors
in the organ baths (Online Figures 5A to 5C). In addi-
tion, impairment of EDR induced by T2DM RBCs was
prevented when the RBCs were pre-incubated for 1 h
with gp91 ds-tat before the 18-h incubation (OnlineFigure 6A), whereas the inhibitor incubated with
Healthy RBCs had no effect on EDR (Online Figure 6B).
These observations suggest that there was no carry-
over effect to the functional studies and that the
improvement in EDR induced by the inhibitors during
pre-incubation with RBCs results from inhibitory ef-
fects in RBCs acting on the vascular wall.
ARGINASE IS UP-REGULATED IN RBCs FROM
PATIENTS WITH T2DM BY A ROS-DEPENDENT
MECHANISM. Arginase activity and arginase I pro-
tein expression were signiﬁcantly elevated in T2DM
RBCs as compared with Healthy RBCs (Figures 3A and
3C). Arginase I protein expression was elevated in
FIGURE 3 Mutual Regulation Between Arginase and ROS in RBCs
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(A) Arginase activity in Healthy RBCs (n ¼ 15) and T2DM RBCs (n ¼ 20). (B) Arginase activity in T2DM RBCs following 24-h incubation with the ROS scavenger NAC
(n ¼ 8). Protein expression of (C) arginase I, (D) NOX1, and (E) NOX2 normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in T2DM RBCs (n ¼ 8 to 9)
and Healthy RBCs (n ¼ 8). Reactive oxygen species formation in Healthy RBCs and T2DM RBCs in the absence and presence of (F) the arginase inhibitor 2(S)-amino-6-
boronohexanoic acid (ABH) (n ¼ 9) and (G) the nitric oxide synthase inhibitor L-NAME (n ¼ 8). (H) Hydrogen peroxide formation in Healthy RBCs and T2DM RBCs
(n ¼ 12). Values are mean  SEM. *p <0.05, **p <0.01. Abbreviations as in Figures 1 and 2.
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Author's Personal CopyT2DM RBCs (Figure 3C), whereas no arginase II was
detected. Interestingly, NAC decreased arginase ac-
tivity in T2DM RBCs (Figure 3B) but not Healthy RBCs
(Online Figure 7C). Moreover, ROS formation was
increased in T2DM RBCs in comparison with Healthy
RBCs (Figures 3F and 3G). The ROS formation was
attenuated by ABH (Figure 3F) and the NOS inhibitor
Nu-Nitro-L-arginine methyl ester hydrochloride
(L-NAME) (Figure 3G) in T2DM RBCs but not in
Healthy RBCs (Online Figures 7E and 7F). H2O2
formation was increased in T2DM RBCs (Figure 3H).
In addition, NOX2 expression but not NOX1 expres-
sion (p ¼ 0.19) was signiﬁcantly increased in T2DM
RBCs (Figures 3D and 3E). These observations indicate
a vicious cycle in which ROS, likely derived from
NOX2 and uncoupled NOS, increases RBC arginase
activity in T2DM that, in turn, stimulates ROS pro-
duction. High glucose slightly but signiﬁcantlyincreased arginase activity in Healthy RBCs (Online
Figure 7A). This increase was not affected by NAC
(Online Figure 7A). Further, high glucose did not
affect ROS formation in Healthy RBCs (Online
Figure 7D).
RBC-INDUCED UP-REGULATION OF VASCULAR
ARGINASE ACCOUNTS FOR ENDOTHELIAL
DYSFUNCTION IN T2DM. We next investigated the
molecular mechanisms at the vascular level for the
development of endothelial dysfunction induced by
T2DM RBCs. Arginase activity in aortic rings and hu-
man carotid arterial ECs (HCATECs) was increased
following incubation with T2DM RBCs as compared
with Healthy RBCs or KH buffer (Figures 4A and 4B).
Co-incubation with NAC or catalase abolished the in-
crease in aortic arginase activity induced by T2DM
RBCs (Figure 4A), but not in vessels incubated with
Healthy RBCs or KH buffer (Online Figures 7G and 7H).
FIGURE 4 Vascular Arginase Activity and Expression Proﬁle Following RBC Incubation
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(A) Arginase activity in isolated rat aortas following incubation with buffer, Healthy RBCs, and T2DM RBCs for 18 h in the absence and presence of the ROS scavenger
NAC (n ¼ 5) and hydrogen peroxide decomposition catalyst catalase (n ¼ 7). (B) Arginase activity in cultured human carotid arterial endothelial cells (HCATECs)
incubated with buffer, Healthy RBCs, and T2DM RBCs for 24 h (n ¼ 5 to 7). (C) mRNA level of arginase I in aortas incubated with buffer, Healthy RBCs, and T2DM RBCs
for 8 h in the absence and presence of NAC (n ¼ 5 to 13). (D)Western blot images of arginase I, arginase II, NOX1, and NOX2 in isolated rat aortas incubated with buffer,
Healthy RBCs, and T2DM RBCs for 18 h. Quantiﬁcation of protein expression of (E) arginase I, (F) NOX1, and (G) NOX2 normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) in isolated rat aortas incubated with buffer, Healthy RBCs, and T2DM RBCs for 18 h (n ¼ 5 to 6). Values are mean  SEM. *p <0.05,
**p <0.01, ***p <0.001. Abbreviations as in Figures 1 and 2.
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Author's Personal CopyThese observations indicate that H2O2 likely serves
as a mediator initiating signaling between RBCs
and the vascular wall. Vascular arginase I protein
level was also elevated by T2DM RBCs (Figures 4D
and 4E). Immunohistochemical analysis showed
that arginase I was abundantly expressed in ECs and
smooth muscle cells (SMCs) following incubation
with T2DM RBCs (Figure 5). No arginase II protein
was detected using either Western blot or immuno-
histochemistry (Figure 4D, Online Figure 8). Incu-
bation with T2DM RBCs induced an increase in rat
aortic messenger RNA (mRNA) level of arginase I
that was evident at 8 h (Figure 4C, Online Figure 7J).
The increase in vascular arginase I mRNA induced by
T2DM RBCs was attenuated by NAC (Figure 4C),
whereas NAC had no effect following incubation
with Healthy RBCs (Online Figure 7I). NOX1 but not
NOX2 protein expression in rat aortas was increased
by T2DM RBCs (Figures 4D, 4F, and 4G).The impairment of aortic EDR induced by T2DM
RBCs was fully recovered by inhibition of vascular
arginase with ABH (Figure 6A), scavenging of ROS
with NAC (Figure 6B), apocynin (Figure 6C), ML171
(Figure 6D), and catalase (Figure 6E). By contrast, the
NOX2 inhibitors gp91 ds-tat (Figure 6F) and
GSK2795039 (data not shown) failed to improve EDR
in rat aortas incubated with T2DM RBCs, a ﬁnding
consistent with the lack of changes in NOX2 protein
expression. None of the inhibitors applied in the or-
gan baths mentioned previously had any effects on
EDR in vessels incubated with Healthy RBCs
(Online Figures 9A to 9F) or KH buffer (Online
Figures 10A to 10F).
DISCUSSION
The main ﬁndings of the present study are as follows:
1) T2DM RBCs induced endothelial dysfunction in rat
FIGURE 5 Immunohistological Expression of Arginase I in Rat Aortas Incubated With Buffer, Healthy RBCs, and T2DM RBCs for 18 h
(n ¼ 3)
Rabbit immunoglobulin G was used as an isotype control for rabbit primary antibody (shown in insets). The black arrows indicate endothelial
cells, and the white arrows indicate smooth muscle cells. Abbreviations as in Figure 1.
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Author's Personal Copyand human arteries; 2) the endothelial dysfunction
induced by T2DM RBCs was attenuated by arginase
inhibition, ROS scavenging, and H2O2 decomposition
at both the RBC and vascular levels; 3) arginase ac-
tivity, arginase I expression, NOX2 expression, ROS
formation, and H2O2 production were increased in
T2DM RBCs; 4) the increased ROS production in T2DM
RBCs was driven by arginase; and 5) T2DM RBCs
increased vascular arginase activity and arginase I
expression through a ROS-dependent mechanism.
Our ﬁndings demonstrate a novel disease mechanism
in T2DM by which RBCs induce vascular endothelial
dysfunction through up-regulation of arginase I and
ROS signaling.
Studies have revealed that RBCs contribute to
vascular function and integrity, in addition to their
function as oxygen transporters (6). Although several
studies have implied a role of RBCs in regulation of
vascular function in diabetes (7,8), key mechanisms
are unclear, and direct evidence behind the interac-
tion of RBCs with the endothelium in T2DM is lacking.
We therefore aimed to investigate the role of RBCs as
novel mediators of endothelial dysfunction in pa-
tients with T2DM. Indeed, T2DM RBCs were demon-
strated to induce endothelial dysfunction in both
healthy rat aortas and internal mammary arteries
from nondiabetic patients. In accordance with our
previous ﬁndings (13), vascular endothelial dysfunc-
tion was demonstrated in vivo in the cohort of pa-
tients with T2DM who donated RBCs for the in vitro
experiments, thus suggesting that RBCs play an
important role and may serve as a key mechanism for
the development of vascular endothelial dysfunction
observed in vivo in T2DM. In addition to humanRBCs, RBCs from GK rats induced endothelial
dysfunction to an extent similar to that observed in
GK rat aortas. This ﬁnding suggests that it is the T2DM
per se that contributes to the detrimental effect of
RBCs rather than co-morbidities, co-medication, or
other confounding factors associated with the group
of patients with T2DM.
We and other investigators previously demon-
strated that arginase is up-regulated in the vascula-
ture in both animal models and patients with T2DM,
and it contributes to resistance artery and microvas-
cular endothelial dysfunction (4,5,13,14). Of further
interest, we demonstrated that arginase expressed in
RBCs regulated cardiac function in an ex vivo model
of ischemia and reperfusion (9). This ﬁnding indicates
an important interaction between RBC arginase and
cardiovascular function. We therefore hypothesized a
potential involvement of arginase in RBC-induced
endothelial dysfunction in T2DM. Accordingly, argi-
nase activity is signiﬁcantly elevated in T2DM RBCs as
compared with Healthy RBCs. The status of arginase
in RBCs from patients with T2DM remains debatable.
The majority of arginase is bound to the membrane of
RBCs, with small amounts present in the cytoplasm
(15). Arginase activity has been found to be elevated
in membrane fractions of RBCs in T2DM (10), but it
has been shown to be decreased in RBCs from pa-
tients with T2DM at ﬁrst clinical onset (16). This
variation may indicate different levels of arginase
activity at different stages of T2DM. We also demon-
strated increased expression of arginase I protein.
These observations suggest that up-regulation of
arginase I already exists in the early phase of
erythropoiesis (e.g., in reticulocytes). Indeed,
FIGURE 6 Functional Involvement of Vascular Arginase and ROS in Endothelial Dysfunction in T2DM
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Endothelium-dependent relaxation to ACh in isolated rat aortas following incubation with buffer, Healthy RBCs, and T2DM RBCs for 18 h. Following the 18-h incubation
with red blood cells from patients with T2DM and rinsing, the rat aortas were treated with (A) the arginase inhibitor 2(S)-amino-6-boronohexanoic acid (ABH) (n ¼ 6),
(B) the ROS scavenger NAC (n ¼ 7), (C) the NOX inhibitor apocynin (n ¼ 3), (D) the selective NOX1 inhibitor ML171 (n ¼ 5), (E) the hydrogen peroxide decomposition
catalyst catalase (n ¼ 3 to 4), and (F) the selective NOX2 inhibitor gp 91 ds-tat (n ¼ 3). Values are mean  SEM. *p <0.05, **p <0.01, ***p <0.001 vs. buffer;
†p <0.05, ††p <0.01 effect of drug representing the concentration-response relation by 2-way analysis of variance. Parentheses indicate that the inhibitors were
added in the organ baths following the 18 h RBC incubation. Abbreviations as in Figures 1 and 2.
J A C C V O L . 7 2 , N O . 7 , 2 0 1 8 Zhou et al.
A U G U S T 1 4 , 2 0 1 8 : 7 6 9 – 8 0 Red Blood Cells and Endothelial Function in Diabetes
777
Author's Personal Copyreticulocytes isolated from an animal model of dia-
betes had increased arginase activity compared with
reticulocytes from nondiabetic controls (17). ROS
scavenging decreased arginase activity in T2DM RBCs,
and the increased ROS formation in T2DM RBCs was
attenuated by arginase inhibition. The observed
up-regulation of arginase and ROS is of critical
importance for the detrimental effect of RBCs on
endothelial function. Thus, inhibition of RBC arginase
prevented the impairment of EDR induced by T2DM
RBCs. Moreover, ROS scavenging, H2O2 decomposi-
tion, NOX inhibition, and NOX2 inhibition also pre-
vented development of endothelial dysfunction, a
ﬁnding supported by elevated levels of H2O2 andNOX2 protein in T2DM RBCs. Catalase reversed
endothelial dysfunction induced by T2DM RBCs, thus
suggesting an important role of RBC-derived H2O2 in
RBC-induced endothelial dysfunction, but it attenu-
ated endothelial function in the presence of Healthy
RBCs. In line with previous observations indicating
that H2O2 may mediate EDR (18), this ﬁnding may
indicate a role of RBC-derived H2O2 in the regulation
of endothelial function under healthy conditions.
Together with the evidence that increased ROS
formation was attenuated by NOS inhibition, the
present data suggest a mutual regulation between
NOX2-derived and uncoupled NOS-derived ROS and
arginase behind RBC dysfunction in T2DM.
CENTRAL ILLUSTRATION Interaction Between Red Blood Cells and Endothelium
Zhou, Z. et al. J Am Coll Cardiol. 2018;72(7):769–80.
Red blood cells (RBCs) from patients with type 2 diabetes mellitus induce endothelial dysfunction. At the red blood cell level, up-regulated arginase I
causes nitric oxide synthase (NOS) uncoupling, leading to reactive oxygen species production. The reactive oxygen species are also derived from acti-
vation of reduced nicotinamide adenine dinucleotide phosphate oxidase (NOX) 2 in RBCs in type 2 diabetes mellitus, which mutually interact with arginase I,
thus resulting in endothelial dysfunction. The reactive oxygen species, speciﬁcally hydrogen peroxide (H2O2), may play a crucial role in the interplay
between red blood cells and endothelium. H2O2 derived from RBCs in type 2 diabetes mellitus induces increased vascular arginase activity. Together with
vascular NOX1-derived H2O2, up-regulation of vascular arginase accounts for endothelial dysfunction in type 2 diabetes mellitus.
Zhou et al. J A C C V O L . 7 2 , N O . 7 , 2 0 1 8
Red Blood Cells and Endothelial Function in Diabetes A U G U S T 1 4 , 2 0 1 8 : 7 6 9 – 8 0
778
Author's Personal CopyHigh glucose slightly but signiﬁcantly increases
arginase activity in Healthy RBCs. The biological
signiﬁcance of the effect of glucose incubation on
arginase activity in relation to the elevated RBC
arginase in T2DM is unclear, however. The elevated
arginase activity in T2DM RBCs was ROS dependent,
whereas the increase in RBC arginase by glucose in
Healthy RBCs was not signiﬁcantly changed by ROS
scavenging. Similarly, there is increased ROS pro-
duction in T2DM RBCs, but incubation of Healthy
RBCs with high glucose did not increase ROS pro-
duction. Thus, several differences exist between in-
cubation with high glucose ex vivo and T2DM, and ittherefore seems less likely that the slight increase in
arginase activity induced by high glucose is a single
trigger for the larger difference observed between
T2DM RBCs and Healthy RBCs and also for the
endothelial dysfunction induced by T2DM RBCs. Hy-
perglycemia is only 1 of multiple factors contributing
to RBC and endothelial dysfunction in T2DM. Future
studies are warranted to clarify the role of long-term
hyperglycemia in RBC function in T2DM.
We also demonstrated that alterations of the
T2DM RBCs induce speciﬁc changes in vascular gene
and protein expression and enzyme activity that
translate into functional changes. RBCs induced
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Changes in the
function of erythrocytes induced by ROS stimulating arginase I
cause endothelial dysfunction in patients with T2DM.
TRANSLATIONAL OUTLOOK: Additional studies are needed
to develop therapeutic interventions that address this mecha-
nism of endothelial injury and assess their impact on vascular
outcomes.
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Author's Personal Copyincreased arginase activity in aortas and cultured
human carotid arterial ECs, as well as increased
arginase I mRNA and protein expression in aortas.
The functional importance of endothelial arginase
was demonstrated by the ability of the arginase in-
hibitor to fully reverse the endothelial dysfunction
in rat aortas induced by T2DM RBCs. Furthermore,
ROS scavenging and H2O2 decomposition resulted in
decreased vascular arginase activity in T2DM RBCs, a
ﬁnding suggesting cross-talk between RBC ROS and
vascular arginase I. Collectively, our data demon-
strate a crucial role of both RBC and vascular argi-
nase in the development of endothelial dysfunction
by an ROS-dependent mechanism in T2DM.
T2DM RBCs also affect vascular oxidative stress,
as revealed by the observation that ROS scavenging
and H2O2 decomposition following RBC incubation
restored the impaired EDR. ECs express 4 NOX iso-
forms (NOX1, 2, 4, and 5), of which NOX1 and NOX2
are the most important sources of ROS formation
and endothelial dysfunction in experimental animals
with diabetes (19). In the present study, nonselective
NADPH oxidase inhibition and selective NOX1 but
not selective NOX2 inhibition improved EDR
following incubation with T2DM RBCs. This is
consistent with the increased protein expression of
vascular NOX1 induced by T2DM RBCs. These ob-
servations suggest that vascular NOX1-derived ROS
is involved in the impaired EDR induced by T2DM
RBCs.
STUDY LIMITATIONS. Patients with T2DM had other
comorbidities and ongoing medication, which may
inﬂuence the effect of the RBCs. However, RBCs
from GK rats, a pure T2DM model, also impaired EDR
to an extent comparable to that induced by RBCs
from patients with T2DM and to that observed in
aortas isolated from GK rats, thereby suggesting the
T2DM per se is capable of inducing endothelial
dysfunction. Moreover, several pharmacological
compounds of our diabetic patients are known to
improve endothelial function by various mecha-
nisms (20). It may therefore be expected that the
medication may even counteract the observed
negative effect, thus leading to an underestimation
of the difference between the diabetic patients and
the healthy subjects. Interestingly, RBCs collected
from a subgroup of patients without statin treatment
induced endothelial dysfunction that was compara-
ble to that induced by the group with statin treat-
ment. The study demonstrates that RBCs induce
endothelial dysfunction in isolated arteries ex vivo.
Despite the observations that the patients who
donated the RBCs had impaired endothelial functionin vivo, and that arginase inhibition improves
resistance and microvascular endothelial function in
patients with T2DM (4,5), it cannot be determined to
what degree the RBCs contribute to endothelial
dysfunction in T2DM patients in vivo. However, only
an isolated vascular model permits the identiﬁcation
of the speciﬁc pathophysiological mechanism medi-
ated by RBCs because it is not feasible to distinguish
effects mediated by RBCs from those of other cell
types in the in vivo setting.
CONCLUSIONS
We demonstrate a novel disease mechanism by which
RBCs induce endothelial dysfunction in T2DM
(Central Illustration). This effect is triggered by
increased NOX2- and NOS-derived ROS formation
driven by arginase in the RBCs. H2O2 seems to play a
crucial role in the interplay between RBCs and
vasculature that leads to endothelial dysfunction in
T2DM. This involves an RBC-derived H2O2-induced
increase in vascular arginase I and vascular H2O2
formation derived from vascular NOX1, which ulti-
mately induce endothelial dysfunction. Our ﬁndings
suggest that RBCs, speciﬁcally RBC arginase I, are
potential therapeutic targets for the treatment of
endothelial dysfunction in patients with T2DM.
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